Attached files
file | filename |
---|---|
8-K - RADIENT PHARMACEUTICALS Corp | v196127_8k.htm |
EX-10.1 - RADIENT PHARMACEUTICALS Corp | v196127_ex10-1.htm |
Radient
Pharma Contact:
Kristine
Szarkowitz
Director-Investor
Relations
|
|
FOR IMMEDIATE RELEASE |
kszarkowitz@radient-pharma.com
|
(Tel
:) 206.310.5323
|
RADIENT
PHARMACEUTICALS RESCHEDULES 2010 ANNUAL
SHAREHOLDERS
MEETING
(TUSTIN,
CA) September 7,
2010/Marketwire – Radient Pharmaceuticals Corporation (RPC) (NYSE
AMEX: RPC -
News) announced
today, it will reschedule its annual shareholders’ meeting originally scheduled
on August 31, 2010.
As noted
in its Form 8-K filed today, due to the continuing Securities and Exchange
Commission (“SEC”) review of RPC’s proxy statement and periodic reports that RPC
is required to submit to its shareholders with the proxy statement, RPC was
unable to file and mail its definitive proxy statement so as to
give shareholders proper notice of the August 31, 2010 meeting
date. RPC filed its response to the SEC’s most recent comment letter
on August 31, 2010 and continues to work diligently with its outside securities
counsel and independent auditors, as well as communicating with the SEC
reviewers handling these filings, to re-schedule the meeting as soon as
possible. There is no assurance that the SEC will clear RPC’s filings
after reviewing the response and the SEC is entitled to issue additional
comments if it deems them necessary. RPC will continue to respond to
any additional comments as quickly as possible and will continue to do whatever
we can to clear the comments as soon as possible. Due to the ongoing comment
period with the SEC, RPC management determined it was prudent to wait until the
Company is closer to clearing the comments before setting a new meeting
date. Once a date has been determined RPC will issue a press release
announcing meeting details.
As a
result of the Shareholders’ meeting delay, RPC is not in compliance with certain
terms contained in the notes issued in the financing it completed in March and
April 2010. RPC is currently negotiating with such note holders to
remediate this issue. Additional details can be found in the Current
Report on Form 8K that RPC filed earlier today. For additional information
on Radient Pharmaceuticals, ADI and its portfolio of products visit the
Company’s corporate website at www.Radient-Pharma.com.
For Investor Relations information contact Kristine Szarkowitz at IR@Radient-Pharma.com
or 1.206.310.5323.
About
Radient Pharmaceuticals:
Forward Looking
Statements:
Safe
Harbor Statement under the Private Securities Litigation Reform Act of 1995: The
statements contained in this document include certain predictions and
projections that may be considered forward-looking statements under securities
law. These statements involve a number of important risks and uncertainties that
could cause actual results to differ materially including, but not limited to,
the performance of joint venture partners, as well as other economic,
competitive and technological factors involving the Company’s operations,
markets, services, products, and prices. With respect to Radient Pharmaceuticals
Corporation, except for the historical information contained herein, the matters
discussed in this document are forward-looking statements involving risks and
uncertainties that could cause actual results to differ materially from those in
such forward-looking statements.
###